Sugi Predict

Sugi Predict / Compounds / SCHEMBL578012

SCHEMBL578012

SCHEMBL578012

CC(C)(C)OC(=O)N1CCN(CCN2C(=O)c3ccccc3C2=O)CC1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ ALDH1A1 P00352 3/20 0.53
▸ CHRM2 P08172 1/20 0.52
▸ CHRM4 P08173 1/20 0.52
▸ CHRM1 P11229 1/20 0.52
▸ CHRM3 P20309 1/20 0.52
▸ POLB P06746 1/20 0.51
▸ RXFP1 Q9HBX9 1/20 0.51
▸ HTR1A P08908 1/20 0.50
▸ ACKR3 P25106 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ DRD2 P14416 3/20 0.47
▸ DRD3 P35462 3/20 0.47
▸ MAPT P10636 1/20 0.47
▸ DTYMK P23919 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29659287 1.00 KMT2A (0.57) KMT2AMEN1ALDH1A1CHRM2CHRM4
SCHEMBL17844904 0.93 DRD2 (0.56) KMT2AMEN1ALDH1A1HTR1ADRD2
SCHEMBL29391217 0.93 DRD2 (0.56) KMT2AMEN1ALDH1A1HTR1ADRD2
SCHEMBL29944565 0.93 ALDH1A1 (0.57) KMT2AMEN1ALDH1A1HTR1ADRD2
SCHEMBL829637 0.93 ALDH1A1 (0.57) KMT2AMEN1ALDH1A1HTR1ADRD2
SCHEMBL12263981 0.91 MAOB (0.57) KMT2AMEN1ALDH1A1HTR1ADRD2
SCHEMBL29263692 0.91 MAOB (0.57) KMT2AMEN1ALDH1A1HTR1ADRD2
SCHEMBL22123837 0.90 ALDH1A1 (0.49) KMT2AMEN1ALDH1A1CHRM2CHRM4
SCHEMBL8406113 0.89 ACKR3 (0.52) KMT2AMEN1ALDH1A1CHRM2CHRM4
SCHEMBL8406115 0.89 ALDH1A1 (0.48) KMT2AMEN1ALDH1A1CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118994147-A GPX4 protein degradation agent based on hydrophobic tag and preparation method and application thereof 中国海洋大学 2024-11-22 — — CN disclosed
US-12023383-B2 Lipid compositions ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-02 — — US disclosed
US-12023383-B2 Lipid compositions ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-02 — — US disclosed
US-20240066129-A1 LIPID COMPOSITIONS ARBUTUS BIOPHARMA CORPORATION (US) 2024-02-29 — — US disclosed
US-20240066129-A1 LIPID COMPOSITIONS ARBUTUS BIOPHARMA CORPORATION (US) 2024-02-29 — — US disclosed
US-11472811-B2 Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist BEIGENE, LTD. (KY) 2022-10-18 — — US disclosed
CN-114524781-A Lipid composition 阿布特斯生物制药公司 2022-05-24 — — CN disclosed
CN-112313234-B Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists 百济神州有限公司 2022-04-29 — — CN disclosed
US-20210198267-A1 PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST BEONE MEDICINES I GMBH (CH) 2021-07-01 — — US disclosed
US-20210198267-A1 PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST BEONE MEDICINES I GMBH (CH) 2021-07-01 — — US disclosed
US-20120128760-A1 LIPID COMPOSITIONS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-05-24 — — US disclosed
US-20120128760-A1 LIPID COMPOSITIONS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-05-24 — — US disclosed
CN-102421417-A Lipid composition ALNYLAM PHARMACEUTICALS INC 2012-04-18 — — CN disclosed
EP-2416760-A1 LIPID COMPOSITIONS Alnylam Pharmaceuticals, Inc. (US) 2012-02-15 — — EP disclosed
WO-2010129709-A1 LIPID COMPOSITIONS ALNYLAM PHARMACEUTICALS, INC. (US) 2010-11-11 — — WO disclosed
WO-2010129709-A1 LIPID COMPOSITIONS ALNYLAM PHARMACEUTICALS, INC. (US) 2010-11-11 — — WO disclosed
EP-1060163-B1 NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES KLINGE CO CHEM PHARM FAB (DE) 2005-10-12 — — EP disclosed
US-6903118-B1 Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides KLINGE PHARMA GMBH (DE) 2005-06-07 — — US disclosed
EP-1060163-A1 NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES Klinge Pharma GmbH (DE) 2000-12-20 — — EP disclosed
WO-1999031063-A1 NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES KLINGE PHARMA GMBH (DE) 1999-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198267-A1 PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST ADORA2A, ADORA3, ADORA2B KMT2A 1957/4885MEN1 3320/4885ALDH1A1 1050/4885
US-20120128760-A1 LIPID COMPOSITIONS SGMS1, SGMS2, LIPA KMT2A 4812/4885MEN1 1182/4885ALDH1A1 2382/4885
US-20240066129-A1 LIPID COMPOSITIONS SGMS1, SGMS2, LIPA KMT2A 4812/4885MEN1 1182/4885ALDH1A1 2382/4885
US-12023383-B2 Lipid compositions SGMS1, SGMS2, LIPA KMT2A 4812/4885MEN1 1182/4885ALDH1A1 2382/4885
US-11472811-B2 Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist ADORA2A, ADORA3, ADORA2B KMT2A 1957/4885MEN1 3320/4885ALDH1A1 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.